Trxade Group Inc.’s (TRXD) Fiscal 2019 Off to Record Start with Q1 Revenue of $1.5 Million
- TRXD sales grew to $1.5 million in Q1 2019; operating income also rose when compared to the same period of the prior year
- The company is adding new independent pharmacies and increasing pharmacy sales
- Mail-order pharmacy services and a newly launched mobile app offer lower prescription drug costs for U.S. consumers
Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical services company that offers a web-based e-hub buying platform for transactions between independent pharmacists and drug manufacturers, reported record Q1 2019 revenues. The company also reported (http://nnw.fm/znW3v) higher operating income, as it sees “continuing revenue growth and profitability in 2019.”
TRXD reported Q1 2019 sales of $1.5 million, as compared to $852,923 in revenues for the same period of the previous year. Operating income grew in Q1 2019 to $171,759 from $98,728 in Q1 2018. Net income reached $125,229 for Q1 2019, as compared to $82,269 for the same period of the previous year.
“Our 2019 fiscal year is off to a record start and in line with our primary objective of expanding our membership base while simultaneously focusing on increasing their utilization rates,” Trxade Group chairman and CEO Suren Ajjarapu stated in a news release. “At the end of the first quarter, we reported record platform subscribers and transactional revenue along with higher net and operating profits for the same period.”
TRXD’s proprietary trading platform enables independent pharmacies to buy online, directly from national pharmaceutical suppliers. The company attributed its revenue growth to an increase in its fee income from this web-based supplier-to-pharmacy trading platform, as well as increased pharmaceutical sales from its wholly owned subsidiary, Community Specialty Pharmacy LLC.
“Our proprietary software trading platform at www.Trxade.com, which enables independent pharmacies to purchase drugs, is adding new members on a monthly basis and, as a result, enabling us to experience strong top and bottom line growth across the board,” Ajjarapu added. In Q1 2019, TRXD added more than 400 new independent pharmacies, which were successfully onboarded on to the Trxade software trading platform.
On the consumer side, TRXD operates a full-service, mail-order business with pharmacy, warehouse and drug-delivery services, along with a mobile app – www.Delivmeds.com – that enables home delivery. These B2C offerings lower drug costs for U.S. consumers, the company said, and directly challenge the inefficient value chain by providing drug-price transparency and efficient buying and delivery of drugs.
For more information, visit the company’s website at www.TrxadeGroup.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- TRXD sales grew to $1.5 million in Q1 2019; operating income also rose when compared to the same period of the prior year
- The company is adding new independent pharmacies and increasing pharmacy sales
- Mail-order pharmacy services and a newly launched mobile app offer lower prescription drug costs for U.S. consumers
Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical services company that offers a web-based e-hub buying platform for transactions between independent pharmacists and drug manufacturers, reported record Q1 2019 revenues. The company also reported (http://nnw.fm/znW3v) higher operating income, as it sees “continuing revenue growth and profitability in 2019.”
TRXD reported Q1 2019 sales of $1.5 million, as compared to $852,923 in revenues for the same period of the previous year. Operating income grew in Q1 2019 to $171,759 from $98,728 in Q1 2018. Net income reached $125,229 for Q1 2019, as compared to $82,269 for the same period of the previous year.
“Our 2019 fiscal year is off to a record start and in line with our primary objective of expanding our membership base while simultaneously focusing on increasing their utilization rates,” Trxade Group chairman and CEO Suren Ajjarapu stated in a news release. “At the end of the first quarter, we reported record platform subscribers and transactional revenue along with higher net and operating profits for the same period.”
TRXD’s proprietary trading platform enables independent pharmacies to buy online, directly from national pharmaceutical suppliers. The company attributed its revenue growth to an increase in its fee income from this web-based supplier-to-pharmacy trading platform, as well as increased pharmaceutical sales from its wholly owned subsidiary, Community Specialty Pharmacy LLC.
“Our proprietary software trading platform at www.Trxade.com, which enables independent pharmacies to purchase drugs, is adding new members on a monthly basis and, as a result, enabling us to experience strong top and bottom line growth across the board,” Ajjarapu added. In Q1 2019, TRXD added more than 400 new independent pharmacies, which were successfully onboarded on to the Trxade software trading platform.
On the consumer side, TRXD operates a full-service, mail-order business with pharmacy, warehouse and drug-delivery services, along with a mobile app – www.Delivmeds.com – that enables home delivery. These B2C offerings lower drug costs for U.S. consumers, the company said, and directly challenge the inefficient value chain by providing drug-price transparency and efficient buying and delivery of drugs.
For more information, visit the company’s website at www.TrxadeGroup.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
